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In contrast to G protein-coupled receptors, for which chemi-
cal and peptidic inhibitors have been extensively explored, few
compounds are available that directly modulate heterotrimeric
G proteins. Active Gq binds its two major classes of effectors,
the phospholipase C (PLC)- isozymes and Rho guanine nucle-
otide exchange factors (RhoGEFs) related to Trio, in a strikingly
similar fashion: a continuous helix-turn-helix of the effectors
engages Gq within its canonical binding site consisting of a
groove formed between switch II and helix3. This information
was exploited to synthesize peptides that bound active Gq in
vitro with affinities similar to full-length effectors and directly
competed with effectors for engagement of Gq. A representa-
tive peptide was specific for active Gq because it did not bind
inactive Gq or other classes of active G subunits and did not
inhibit the activation of PLC-3 by G12. In contrast, the pep-
tide robustly prevented activation of PLC-3 or p63RhoGEF by
Gq; it also prevented G protein-coupled receptor-promoted
neuronal depolarization downstream of Gq in the mouse pre-
frontal cortex.Moreover, a genetically encoded formof this pep-
tide flanked by fluorescent proteins inhibited Gq-dependent
activation of PLC-3 at least as effectively as a dominant-nega-
tive form of full-length PLC-3. These attributes suggest that
related, cell-penetrating peptides should effectively inhibit
active Gq in cells and that these and genetically encoded
sequencesmay find application asmolecular probes, drug leads,
and biosensors tomonitor the spatiotemporal activation of Gq
in cells.
G protein-coupled receptors (GPCRs)3 are the largest family
of cell surface receptors in eukaryotes and regulate essentially
all physiological processes (1–4). Scores of neurotransmitters,
hormones, and other extracellular signalingmolecules promote
conserved conformational changes in GPCRs that favor inter-
actionwith heterotrimericGproteins (G) on the inner leaf-
let of the plasma membrane. The subsequent exchange of GTP
for GDP alters three switch regions within G subunits to pro-
mote dissociation from G (5, 6). These activated subunits
then directly stimulate downstream effectors, leading to prop-
agation and amplification of signaling pathways (7, 8).
Signaling cascades downstream of several hundred different
GPCR are activated by the cognate agonist of these receptors.
Many of these GPCRs, particularly those activated by neu-
rotransmitters, also have been targeted by receptor subtype-
selective agonists and antagonists. Indeed, up to a quarter of
current top-prescribed, Food and Drug Administration-ap-
proved drugs take advantage of GPCR-selective targeting. In
contrast, few molecular probes are available for dissection of
the downstream signaling cascades emanating from these
GPCRs. Most notably, bacterially derived cholera and pertussis
toxins contributed enormously to the initial identification of
Gs and Gi and were subsequently applied to differentiate
Gs- andGi-mediated signaling pathways (9).However, only a
few small molecules have been identified that target G sub-
units, and reliable pharmacological agents that selectively
inhibit these signaling proteins are not generally available (10).
For example, BIM-46174 and BIM-46187 apparently interact
with most G subunits (11, 12), and some selectivity for Gq
has been reported for BIM-46187 (13). In contrast, YM-254890
(14), and related natural products such as FR900359 (15, 16),
specifically inhibit G subunits of the Gq family (17, 18), and a
crystal structure of a G protein heterotrimer bound to
YM-254890 illustrates that this molecule prevents GDP release
and heterotrimer dissociation (19). Unfortunately, synthesis
of cyclic depsipeptides is difficult, and YM-254890 remains
unavailable from commercial sources. The mechanism of this
molecule also precludes inhibition against G subunits in the
GTP-bound state; for example, on mutant proteins that are
constitutively active because of loss of GTPase function.
Linear peptides also have been identified that selectively tar-
get G subunits (20). For example, the G protein regulatory
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(GPR or GoLoco) motif of proteins preferentially binds GDP-
bound Gi subunits with relatively high affinity to decrease
spontaneous nucleotide exchange (21). Small peptides based on
this motif were applied to inhibit D2 dopamine receptor-stim-
ulated potassium channel currents (22). Phage display in com-
bination with Gi1 was also used to generate peptides that spe-
cifically bind G subunits dependent on the state of bound
nucleotide (23–25). One of these peptides preferentially binds
active Gi and Gt and was shown to inhibit the capacity of
Gi1 to be inactivated by RGS12 and to reduce activation of
cGMP phosphodiesterase by Gt in membrane preparations.
A molecular understanding of the binding of G subunits
with their downstream effectors potentially informs the devel-
opment of peptides to pharmacologically antagonize functional
interaction of these signaling cohorts. For example, rearrange-
ment of the switch regions of G subunits creates a hydropho-
bic cleft between switch 2 and  helix 3 that is a major site of
interaction with effectors (26) and potentially exists as a site for
drug targeting. The best understood G/effector interaction is
between Gq and its effectors, the phospholipase C- (PLC-)
isozymes and the relatedDbl family proteins p63RhoGEF, Trio,
and kalirin (27–29). These effectors engage the hydrophobic
cleft of Gq using almost identical sets of interactions derived
from a helix-turn-helix (HTH) substructure (Fig. 1) that is
induced in the effectors upon engagement with Gq. The HTH
of PLC-3 and p63RhoGEF forms themajor interface withGq
in crystal structures of these complexes, whereas secondary
interactions orient the complexes at membranes for efficient
effector activation (30, 31).
Here we show that linear peptides based on the HTH of
PLC-3 specifically bind activated Gq to prevent engagement
and activation of downstream effectors by Gq. These peptides
have no appreciable affinity for either GDP-bound Gq or for
activated forms of other G subunits and should be useful re-
agents for interdicting signaling cascades controlled by Gq.
Indeed, we show that microinjection of HTH-based peptides
into mouse neurons of the prefrontal cortex prevents depolar-
ization downstream ofmuscarinic cholinergic receptor-depen-
dent activation of Gq.
Results
Canonical Effector Interactions with Gq Drive Complex
Formation—Recent structures of activatedGq bound to either
PLC-3 (30) or p63RhoGEF (31) highlight an essentially iden-
ticalmechanism of effector engagement. In both cases, anHTH
of the effector occupies the canonical effector-binding site of
Gq composed of a shallow groove between the 3 helix and
switch II (Fig. 1A). TheHTH is presumed to provide themajor-
ity of favorable interactions promoting complex formation and
buries810Å2 ofGq (5% of the accessible surface) to produce
FIGURE 1. Gq uses a conserved mechanism to engage effectors. A, a helix-turn-helix (H1/H2, cylinders) in either PLC-3 (blue) or p63RhoGEF (yellow)
engages a shallowgrooveonactivatedGq (greenwith switch regions in red) between switch II and3. The structuresofGqbound toeither PLC-3 (PDBcode
3OHM) (30) or p63RhoGEF (PDB code 2RGN) (31)were superimposedusingGq. For clarity, only a singleGq is shown. The expanded regionhighlights residues
inPLC-3 thatdirectly contactGq; contactsboxed in the corresponding sequencealignment.C-term, C terminus;N-term, N terminus.BandC, peptidesderived
from thehelix-turn-helix of PLC-3 selectively bind activeGq.B, fluorescencepolarization (mP, change inmillipolarization)was used tomeasure thebinding
of the indicated G subunits to either a TAMRA-labeled peptide (27-mer(I860A)) derived from the helix-turn-helix of PLC-3 or the equivalent peptide also
containing L859E (27-mer(L859EI860A)). All G subunits were activated with aluminum fluoride except where indicated (no AlF4). C, the above assay was
used to measure affinities of active Gq for the TAMRA-labeled peptides listed. Substitutions include I860A (red) and M869Nle (underlined in red).
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the largest contiguous interface between proteins in these
structures. Deletion of the HTH of PLC-3 (30) or p63RhoGEF
(29) abrogates interaction with Gq; conversely, grafting the
HTH of PLC-3 onto PLC-1 engenders complex formation
with Gq (30).
To more accurately quantify interactions between activated
Gq and HTH peptides, changes in fluorescence polarization
were measured for a set of TAMRA-labeled peptides spanning
the HTH of PLC-3 and titrated with various G subunits (Fig.
1,B andC). A 27-residue peptide (27mer(I860A)), derived from
the complete HTH of PLC-3, bound to activated Gq with
high affinity (Kd400 nM), and complex formation was depen-
dent upon activation because little change in fluorescence
occurred in the absence of aluminum fluoride (Fig. 1B). This
interactionwas also specific forGq because activation of other
G subunits (Gi1, Gt, and Gs) did not result in binding to
the HTH-based peptide. A residue on the HTH that is a major
contributor to this interaction is leucine at position 859 of PLC-
3, and mutating this residue to glutamic acid abolished bind-
ing of the TAMRA-labeled 27-mer(I860A) (Fig. 1B).
The 27-mer(I860A) peptide contains two substitutions rela-
tive to thewild-type sequence: the oxidation-pronemethionine
was replacedwith isosteric L-norleucine, and isoleucine at posi-
tion 860 of full-length PLC-3 was replaced with alanine (Fig.
1C). This second substitution (I860A) was shown previously to
increase the phospholipase activity of PLC-3 in response to
Gq (30) and was assumed to increase the affinity of the com-
plex. Indeed, the substitutions contributed to an approximate
10-fold increase in affinity for activatedGq comparedwith the
equivalent peptide (27-mer) without substitutions (Fig. 1C).
Truncation of the 27-mer by removal of two alanines at its C
terminus (25-mer) led to a minor reduction ( 2-fold) in affin-
ity for Gq. In contrast, shorter peptides lackingmost (13-mer)
or all (10-mer) of the C-terminal helix of the HTH did not bind
activated Gq with measurable affinity.
The robust increase in fluorescence polarization produced
by the complex of TAMRA-27-mer(I860A)with activeGqwas
used in a series of competition binding experiments to assess
the relative affinities of unlabeled peptides for active Gq (Fig.
2). The capacity of unlabeled 27-mer(I860A) to interact with
FIGURE 2. Competition assay tomeasure affinities of peptides and effectors for Gq. A and B, individual unlabeled peptides were titrated into a solution
of Gq bound to TAMRA-27-mer(I860A), and fluorescence polarization was measured. Ki values were calculated using an equation to convert IC50 to Ki values
in fluorescence-based competition assays (38). The sequence alignment is annotated as in Fig. 1. Inset, circular dichroism spectra for select peptides. Substi-
tutions include I860A (red) and M869Nle (underlined in red). C, competition assay used to measure affinities of the indicated effectors for Gq activated with
aluminum fluoride.
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Gq was quantified by titrating this peptide into a solution con-
taining 0.4 M TAMRA-labeled peptide and active Gq. The
resulting decrease in fluorescence polarization was quantified,
and aKi (0.3M) for unlabeled 27-mer(I860A) was calculated
as described under “Experimental Procedures” (Fig. 2A). This
Ki was essentially identical to the Kd (0.4 M) determined for
direct binding of the TAMRA-labeled 27-mer(I860A) to active
Gq. Thus, the presence of the TAMRAmoiety does not appre-
ciably affect Gq-HTH complex formation.
A shorter, unlabeled peptide (21-mer(I860A)) that retained
all PLC-3 residues that contact Gq in the complex (30) also
effectively inhibited (Ki 1 M) the binding of TAMRA-27-
mer(I860A). Binding was also more favorable with this peptide
than with the equivalent 21-mer without substitution (Fig. 2A),
which again supports the idea that the I860A substitution
enhances complex formation. The 3-fold decrease in inhibi-
tory activity of 21-mer(I860A) relative to 27-mer(I860A) is con-
sistent with direct binding measurements that showed a slight
decrease in the affinity of the TAMRA-labeled 25-mer relative
to the equivalent 27-mer. This trend also held in comparisons
of the activity of unlabeled, unsubstituted 21-mer of PLC-3 (Ki
3 M) with that of the related 36-mer (Ki1 M) (Fig. 2B).
The reason(s) why the shorter peptides exhibit a small but
consistent decrease in affinity for Gq relative to the longer
forms is unclear. One possibility is that loss of residues either
proximal to or contained within the helices of the HTH motif
destabilizes the secondary structure needed for complex for-
mation with Gq. This destabilization is likely to manifest only
after formation of the complex because, irrespective of their
length, the isolated peptides exhibit minimal helical content
based on circular dichroism spectroscopy (Fig. 2A, inset). If
true, this destabilization would result in higher off rates for the
shorter peptides in complex with Gq.
Peptides (21-mers) corresponding to the HTH portions of
the four PLC- isozymes exhibited a 25-fold range of inhibitory
activities (Fig. 2B). Interestingly, these relative activities corre-
late with the general capacity of Gq to activate these isozymes
(PLC-1 3 2 4) (32, 33), suggesting that Gq-medi-
ated activation of PLC- isozymes is principally a function of
complex formation driven by the affinity of Gq for the HTH
region. Equivalent 21-mers from p63RhoGEF and the related
GEFs Trio and kalirin exhibited Ki values in the range of
25–50M, which is similar to the inhibitory activity observed
with the HTH of PLC-4. Relative to the equivalent portion in
PLC-3, the first helix of the HTH is substantially longer in the
structure of p63RhoGEF bound to Gq. Consistent with previ-
ous results, extension of a peptide of p63RhoGEF to include the
entire first helix increased inhibitory activity15-fold relative
to the cognate 21-mer (Fig. 2B).
The competition assaywas also useful for quantifying relative
affinities of active Gq and full-length effectors. For example,
full-length PLC-3 prevented engagement of active Gq by
TAMRA-27-mer(I860A) with an IC50 of 250 nM (Fig. 2C).
This inhibitory activity was 3-fold greater than that of the
36-mer of PLC-3, indicating that most of the energetically
favorable interactions with Gq reside within the HTH of
PLC-3.
The C-terminal domain of PLC- isozymes is required for
phospholipase activation byGq atmembranes; however,mea-
surements of the contribution of the C-terminal domain to
binding toGq have ranged fromessentially no effect (30, 34) to
promoting complex formation by at least 2 orders ofmagnitude
(35). Related to this discrepancy, a truncated form (residues
1–886) of PLC-3, which retains the HTH but lacks the entire
C-terminal domain, competed for complex formation (Fig. 2C)
with an inhibitory activity within 2-fold of that observed with
full-length PLC-3. This result is consistent with previous
affinity measurements using surface plasmon resonance assays
that indicated that theC-terminal domain of PLC-3 is respon-
sible for less than a 2-fold increase in affinity for Gq relative to
PLC-3(1–886) (30). Conversely, a single substitution (L859E)
within the HTH of full-length PLC-3 that was shown previ-
ously to prevent activation of PLC-3 by Gq (30) completely
abrogated the capacity of full-length PLC-3 to compete with
the TAMRA-labeled peptide for engagement of Gq (Fig. 2C).
In addition, PLC-1 was not responsive to Gq and was inca-
pable of competing with TAMRA-27-mer(I860A) (Fig. 2C).
Finally, a large fragment (residues 155–493) of p63RhoGEF
that includes its HTH effectively competed (IC50 500 nM)
with TAMRA-27-mer(I860A) for engagement of Gq (Fig. 2C).
A relative Ki of 1.9 M was observed for binding of the isolated
HTH of p63RhoGEF to Gq, and, therefore, as was observed
with PLC-3, the majority of favorable interactions for com-
plex formationwithGq residewithin theHTHof p63RhoGEF.
Inhibition of Gq-mediated Signaling in Vitro—Because pep-
tides derived from theHTHof PLC-3 effectively competewith
effectors for engagement of Gq, these peptides should also
prevent the Gq-dependent activation of these effectors. As
illustrated in Fig. 3A, TAMRA-27-mer(I860A) indeed effi-
ciently blocked Gq-mediated activation of purified PLC-3 in
reconstituted lipid vesicles. Inhibition was dependent on the
concentration of peptide as well as Gq. A 5-fold increase in the
concentration of Gq required a corresponding increase in
peptide concentration to achieve equivalent inhibition of phos-
pholipase activity with no change in the shape of the concen-
tration-effect curve. These results are strongly indicative of
direct competitive inhibition by the peptide to prevent func-
tional engagement of PLC-3 by Gq, which is expected if both
peptide and effector share a common interface on Gq.
Although the presence of TAMRA had no apparent effect on
HTH-Gq binding in solution, removal of the TAMRAmoiety
from the peptide reduced inhibition of phospholipase activity
by 5-fold (IC50 200 nM) (Fig. 3B), suggesting that the fluo-
rescent group has nonspecific affinity for membranes. This
idea is also supported by the observation that TAMRA-27-
mer(L859EI860A) did not inhibit Gq-mediated activation
of PLC-3 under identical conditions and that, therefore,
TAMRA per se does not intrinsically inhibit activation.
TAMRA-27-mer(I860A)-mediated inhibition of phospho-
lipase activity was specific for Gq because the peptide did not
inhibit the equivalent activation of PLC-3 by G12 (Fig. 3C).
Indeed, under conditions of synergistic activation of PLC-3 by
both G12 and Gq, only the G-mediated component of
activation appeared to be preserved in the presence of
TAMRA-27-mer(I860A).
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Because the canonical effector-binding surface of Gq is
required for activation of both PLC isozymes and RhoGEFs, the
capacity of 27-mer(I860A) to prevent activation of p63RhoGEF
by Gq was examined. Fluorescent GDP was preloaded onto
RhoA, and the capacity of Gq to stimulate p63RhoGEF-pro-
moted guanine nucleotide exchange by Rho was quantified in
the presence of increasing concentrations of 27-mer(I860A)
(Fig. 4). Activity was sharply reduced by 5 M 27-mer(I860A)
and completely inhibited by 12.5 M 27-mer(I860A).
Inhibition of Gq-mediated Signaling in Cells—Given the
robust capacity of synthetic versions of the HTH of PLC-3 to
inhibit effector activation by Gq using purified components,
versions of the 27-mer were expressed in HEK293 cells and
assessed for their capacity to inhibit Gq-promoted signaling
(Fig. 5).
Activity initially was assessed after expression of full-length
versions of PLC-3 rendered catalytically inactive by substitu-
tion (H332A) of the active site of the lipase (Fig. 5A). This
approach presumed that heterologous expression of PLC-
3(H332A) would act in a dominant-negative fashion to pre-
vent activation of endogenous PLC- in response to agonist
(DOI)-promoted stimulation of the co-expressed,Gq-coupled
5HT2A receptor. Indeed, expression of increasing amounts of
PLC-3(H332A) resulted in essentially complete inhibition of
DOI-stimulated inositol phosphate accumulation. Impor-
tantly, this inhibitory activity was not observed (Fig. 5A) with
PLC-3(H332AL859E), which introduces an additional sub-
stitution, L859E, shown previously to prevent complex forma-
tion of PLC-3 with Gq.
Given the results with PLC-3(H332A), we examined the
inhibitory activity of a construct consisting of the sequence
equivalent to 27-mer(I860A) flanked by two fluorescent pro-
teins to foster intracellular stability. This construct also
potently blocked 5HT2A receptor-dependent activation of
phospholipase C in HEK293 cells (Fig. 5B), and introduction of
L859E into this construct abrogated this inhibitory activity.
Modification of the expression construct to direct posttransla-
tion prenylation of the chimeric HTH peptide resulted in10-
fold more efficient inhibitory activity of the 27-mer(I860A)
sequence, and activity again was lost by introduction of the
L859E mutation into the 27-mer(I860A) sequence (Fig. 5C).
An ultimate goal of this work is to develop peptidomimetic
inhibitors of Gq-promoted signaling in vivo. Toward this goal,
the capacity of these peptides to block neuronal depolarization
was assessed (Fig. 6). Peptides were introduced into neuronal
cells from slices of mouse prefrontal cortex via patch clamp
prior to monitoring depolarization in response to muscarinic
cholinergic receptor-promoted activation of a Gq by themus-
carinic agonist carbachol. Carbachol-stimulated current was
similar to previously recorded activity (36) andwas not affected
FIGURE 3. 27-mer(I860A) inhibits active Gq in lipid vesicles. A and B, lipid vesicles containing [
3H]PIP2 were reconstituted with PLC-3 and Gq prior to
measuringhydrolysis of PIP2 in thepresenceof increasing concentrations of the indicatedpeptides. 120nMGqwasused inB.C, TAMRA-27-mer(I860A) didnot
inhibit the capacity of G12 to activate PLC-3 in lipid vesicles but prevented synergy with Gq.
FIGURE 4. Peptides derived from the helix-turn-helix of PLC-3 inhibit
the capacity of Gq to activate p63RhoGEF. RhoA (100 nM) preloaded
with BODIPY-GDPwas incubatedwith unlabeled GDP (2M), Gq (100 nM),
aluminum fluoride, and the indicated amounts of 27-mer(I860A) prior to
measuring nucleotide exchange using fluorescence (cps, counts per sec-
ond). p63RhoGEF (100 nM) was added as indicated. The tracemarked RhoA
only contains no Gq or p63RhoGEF and indicates spontaneous nucleo-
tide exchange.
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by injection of 10 M 27-mer(L859EI860A). In contrast, 10
M 27-mer(I860A) completely blocked carbachol-stimu-
lated depolarization, and this inhibition was similar to that
observed after the simultaneous application of the musca-
rinic antagonist pirenzepine and 27-mer(L859EI860A).
Thus, a 27-mer based on the HTH of PLC-3 blocks Gq-
dependent signaling in a native neuronal system, and this
inhibitory activity is lost after introduction of a mutation
into the 27-mer known to result in loss of interaction of
PLC-3 with this G protein.
Discussion
The Gq-regulated effectors provide a striking illustration of
converging evolution in disparate signaling proteins.We previ-
ously concluded that the HTH imparts most, if not all of, the
binding energy for the complex of Gq and PLC-3, and this
idea is confirmed here. Indeed, the equivalent region of
p63RhoGEF and related GEFs appears also to embody most of
the binding energy for complexation of these effectors with
Gq.
Although the HTH of PLC-3 is sufficient to recapitulate
high-affinity interaction with active Gq, complex formation
mediated by the HTH is insufficient to elevate phospholipase
activity (30). This follows from the additional requirement of
the 250-residue carboxyl-terminal domain of the PLC,
which, in combination with a membrane surface, is needed
for activation. It remains unclear how these additional com-
ponents impart activation, especially in light of the fact that
the carboxyl-terminal domain likely provides no more than a
2-fold enhancement in affinity for Gq. However, one dis-
tinct possibility is that the carboxyl-terminal domain pro-
ductively orients PLC-3 at membranes for efficient in-
teraction with Gq and hydrolysis of membrane-resident
phosphatidylinositol 4,5-bisphosphate. Other PLC- iso-
zymes would be activated similarly. Indeed, a similar mem-
brane-induced steering of p63RhoGEF and related GEFs with
FIGURE 5.Gq-dependent PLC-3 activity in HEK293 cells is specifically inhibited by genetically encoded versions of the helix-turn-helix of PLC-3.
A–C, HEK293 cellswere co-transfectedwith expressionvectors encoding the5HT2A receptor (100ng) and increasingamountsof PLC-3 (A), YFP-27mer-CFP (B),
or YFP-27mer-CFP-CAAX (C) variants prior to metabolic labeling of inositide pools, receptor activation with DOI (2 M), and quantification of inositol phos-
phates. Protein expression and cellular totals (actin) were verified with Western blotting as shown. Cells without addition of agonist (DOI) were also tested.
FIGURE 6. 27-mer(I860A) inhibitsGq-mediated neuronal depolarization in the prefrontal cortex ofmice. A, pretreatment of a representative prefrontal
cortex neuron with 27-mer(L859EI860A) had no effect on action potential firing in response to CCh (10 M) (top panel). In contrast, depolarization was lost
when 27-mer(I860A) was used (center panel) or the M1 receptor antagonist pirenzepine (2 M) was applied with 27-mer(L859EI860A) (bottom panel). B, the
inward current inducedby carbachol after indicatedpretreatments. Sample sizes included six neurons for the active and inactivepeptides and four neurons for
the active peptide with agonist. *, p 0.05 from baseline. **, p 0.05 between the different experiments n.s., not significant.
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Gq appears to be required for the efficient capacity of these
GEFs to active RhoA (37).
Elucidation of the role of the HTH in Gq binding to PLC-
isozymes together with the observation of dominant negative-
like activity of a lipase-dead formof full-length PLC-3 led us to
investigate the cellular activity of a genetically encoded form of
the HTH. Thus, a peptide optimized for binding to Gq in vitro
proved to markedly inhibit the stimulation of inositol lipid hy-
drolysis occurring downstream of the Gq-linked 5HT2A recep-
tor. The increase in cellular potency of the peptide observed
after introduction of a CAAXmotif almost certainly occurs as a
consequence of increasing the concentration of the peptide
at the membrane, and we conclude that this form of the
27-mer(I860A)provides anoutstanding genetically encoded re-
agent to interdict Gq-stimulated signaling at the cellular level.
It is likely that, although the HTH evolved for optimal physio-
logical activation of PLC- by Gq, it did not evolve to provide
the highest binding affinity. Indeed, a simple alanine substitu-
tion of Ile-860 in PLC-3 was shown previously empirically to
increase Gq-mediated activation of the lipase, and we show
here that such a substitution inHTHalso significantly increases
HTH binding affinity for Gq. Thus, both rational and iterative
screens of other substitutions in HTH should lead to additional
increases in binding affinity in HTH-related peptides, and a
long-term goal of this work is to generate Gq-directed drugs
consisting of these peptides packaged in cell-permeable forms.
The remarkable capacity of the 27-mer(I860A) in a fluorescent
protein-flanked form to blockGq-stimulated inositol lipid sig-
naling also suggests a starting point to develop, for example,
biosensors that image the signaling dynamics of activated Gq.
Experimental Procedures
Peptides—Peptides were either synthesized in-house using a
PS3 solid-state peptide synthesizer (Protein Technologies, Inc.)
or by Anaspec. Peptides in-house were purified with a C18
reversed phased HPLC system with a UV detector, and purity
was determined to be 95% using analytical reversed phase
HPLC. Correct molecular weights of peptides were determined
using MALDI-TOF mass spectrometry.
A subset of TAMRA-labeled PLC-3 peptides following the
C2 domain include 9, 12, 25, and 27 residues (9-, 12-, 25-, and
27-mer). An additional TAMRA-27-mer(I860A) contains a
point mutation, I860A, as well as a non-natural norleucine
(Nle) substituted for methionine at residue 869. All peptides
were amidated on theC terminus and acetylated or labeledwith
TAMRAon theN terminus. Synthesized peptides included dif-
ferent isoforms of PLC- isozymes andDbl familyGEFproteins
shown in Fig. 2B. All peptides were dissolved in 10mMK2HPO4
at concentrations of 1–5 mM.
Fluorescence Polarization Assay—Fluorescence polarization
assays were performed in small-volume cuvettes (Starna Cells,
Inc. Atascadero, CA) in a Fluorolog-3 spectrophotometer
(Horiba Scientific, Edison, NJ) that contained a final volume of
60 l. Fluorescence polarization experiments used 400 nM
TAMRA-labeled peptides and monitored the change in polar-
ization at an excitation wavelength of 554 nm and an emission
wavelength of 569 nm. Increasing amounts of G proteins were
added to the TAMRA-labeled peptide solution to determine
the affinity of Gq for the peptides. Increasing amounts of unla-
beled peptides or proteins were added with 400 nM TAMRA-
27-mer(I860A) and 800 nMGq to determine the IC50 values of
the unlabeled peptides. All experiments contained 10 mM
HEPES (pH 7.0), 150mMNaCl, and 50mMMgCl2 with or with-
out 150 M AlCl3 plus 50 mM NaF. All Kd and IC50 values were
calculated using Prism5 using a one-site binding hyperbola
(Y Bmax	 X/Kd X). For competition experiments, Ki val-
ues were calculated from IC50 values using an equation derived
by Nikolovska-Coleska et al. (38).
Protein Expression and Purification—Gq34, Gq7, PLC-
3, and PLC-3(1–886) were purified from High-Five insect
cells. Gq34 was engineered for high level of expression using
a chimeric form ofGq/i that contained anN-terminal hexahis-
tidine tag followed by residues 1–28 of rat Gai1, a tobacco etch
virus protease site, and residues 35–359 of mouse Gq
(Gq34). Gq7 was constructed similarly. Purification of
Gq34 and Gq7 followed protocols published previously
(30). PLC-3 and PLC-3 (1–886) were purified following pro-
tocols published previously (30). The truncated p63RhoGEF
pleckstrin homology-Dbl homology (PH-DH) extension (155–
493) was purified from Escherichia coli and followed protocols
published previously (29).
Quantification of Phospholipase Activity of Purified PLC-3
Isozymes—Basal phospholipase activity was determined by
combining 330 M L--phosphatidyl ethanolamine and 30 M
L--phosphatidylinositol-4,5-bisphosphate and drying the lip-
ids under N2 in chloroform solution followed by resuspension
by sonication in 20 mM HEPES (pH 7.2). Reactions were incu-
bated for 10 min at 30 °C in a final buffer consisting of 30 mM
HEPES (pH 7.2), 70 mM KCl, 2 mM DTT, 16.7 mM NaCl, 3 mM
EGTA, 200 nM free Ca2, 0.17 mg/ml fatty acid-free BSA, 10
mMNaF, 30MAlCl3, 2.7mMMgCl2, and 20,000 dpm [3H]PIP2
with 200–300 pM of PLC-3 to maintain the linearity of the
enzyme assay. Increasing amount of peptide were added to the
solution containing 60–200 nM Gq or 20–60 nM G12.
Transfection of HEK293 Cells and Quantification of [3H]-
Inositol Phosphate Accumulation—HEK293 cell-based assays
measured accumulation of [3H]inositol phosphates. HEK293
cells were maintained in high-glucose DMEM containing 10%
fetal bovine serum, 100 units/ml penicillin, and 100 g/ml
streptomycin at 37 °C in an atmosphere of 95% air/5% CO2.
HEK293 cells were transfected with 100 ng of DNA that
encoded the 5HT2A receptor in the pcDNA vector and other
indicted DNA vectors using FuGENE 6 (Promega, Madison,
WI) according to the protocol of the manufacturer. The total
amount of transfected DNA was 400 ng and included empty
pcDNA vector to maintain equal amounts of DNA per well.
Twenty-four hours post-transfection, media were exchanged,
and cells were metabolically labeled with 1 Ci of myo-[2-
3H(N)]inositol (American Radiolabeled Chemicals, St. Louis,
MO) at 37 °C for 24 h.Metabolic labeling proceeded at 37 °C for
1 h in a water bath with 10mM LiCl to inhibit phosphatases and
2 M DOI to stimulate the 5HT2A receptor. Incubations were
terminated by aspiration of the culture medium and subse-
quent addition of 50 mM formic acid for 20 min, followed by
neutralization with 150 mM NH4OH. 3H-labeled inositol
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phosphates were isolated and quantified using Dowex
chromatography.
Guanine Nucleotide Exchange Assays—The guanine nucleo-
tide exchange activity of purified p63RhoGEF pleckstrin homo-
logy-Dbl homology extension (155–493) was determined using
a kinetic fluorescence-based assay with RhoA that was pre-
loaded with BODIPY FL-conjugated GDP (BODIPY-GDP,
Molecular Probes) as described previously (39). Exchange
assays were performed using a Fluorolog-3 (Horiba Scientific)
withwavelengths atexcitation 500 nm (slits 1 nm),emission
511 nm (slits 1 nm) and 1.5-ml quartz cuvettes thermostated
at 20 °C while stirring constantly. Reactions were carried out in
exchange buffer consisting of 20 mM Tris (pH 7.5), 150 mM
NaCl, 10mMMgCl2, 10mMNaF, 30MAlCl3, and 10MGDP.
Exchange assays contained BODIPY-GDP-preloaded RhoA
(100 nM) equilibrated in exchange buffer at 20 °C, followed by
addition of p63RhoGEF (100 nM), Gq (100 nM), and the indi-
cated amounts of peptides. Nucleotide exchange was moni-
tored in real time for 2 h at 20 °C.
Electrophysiology—C57BL/6J mice were sacrificed via deep
isoflurane anesthesia and rapid decapitation, and brain slices
containing the prefrontal cortex (PFC) were prepared as
described previously (40, 41). Briefly, brains were rapidly
removed, and 300-m slices were cut on a vibratome (Leica
Biosystems, Buffalo Grove, IL) in a cold (1–4 °C) sucrose-based
external solution. Slices were then immediately placed in nor-
mal artificial cerebrospinal fluid (194mM sucrose, 20mMNaCl,
4.4 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 1.2 mM NaH2PO4, 10
mM glucose, and 26 mM NaHCO3) saturated with 95% O2/5%
CO2 andmaintained at 30 °C and allowed to recover for at least
1 h. Individual slices were then placed in a holding chamber and
continuously perfused with normal oxygenated artificial cere-
brospinal fluid maintained at 30 °C at a rate of 2 ml/min. Neu-
rons were visualized using infrared video microscopy (Olym-
pus, Center Valley, PA). Recording electrodes (3–6 megohms)
were pulled with a Flaming-Brown micropipette puller (Sutter
Instruments, Novato, CA) using thin-walled borosilicate glass
capillaries. Signals were acquired by aMulticlamp 700 B ampli-
fier (Molecular Devices, Sunnyvale, CA), digitized at 10 kHz,
and analyzed usingClampfit 10.2 software (MolecularDevices).
Input resistance and access resistance were continuously mon-
itored throughout all experiments, and those in which changes
in access resistance exceeded 20% were excluded from all data
analyses.
A previous report showed that activation of Gq-coupled
muscarinic acetylcholine 1 receptors (M1) in the PFC elicited a
robust inward current in the PFC (36).Whole-cell slice electro-
physiology was conducted to assess the ability of theGq inhib-
itory peptide to block Gq-mediated M1 receptor signaling in
the PFC in a voltage clamp using a potassium gluconate-based
intracellular solution (135 mM K gluconate, 5 mMNaCl, 2 mM
MgCl2, 10 mM HEPES, 0.6 mM EGTA, 4 mM Na2ATP, 0.4 mM
Na2GTP (pH 7.3), 285–290 mosmol) containing spermine (0.1
mM) and the inactive or active peptide (10 M). Cells were held
at70mV.After achieving a stable 2-min baseline, we assessed
the effects of the M1 receptor agonist carbachol (CCh, 10 M,
bath applied for 10 min) on the holding current in the presence
of the active or inactive Gq inhibitory peptide in the recording
pipette. To confirm the effect observed with the inactive Gq
inhibitory peptide in the recording pipette wasmediated by the
M1 receptor, we assessed the ability of CCh to alter the holding
current in the presence of the M1 receptor antagonist pirenz-
epine (2 M, bath applied for 10 min).
The effects of CCh in the presence of the inactive or active
peptide were analyzed by comparing the change in holding cur-
rent during the final minute of drug application from the final
minute of baseline. To eliminate the possibility that observed
drug effects were due to cell rundown, the holding current dur-
ing the final minute of washout was assessed, and any cells that
did not recover baseline holding potential were removed from
analyses. Amaximumof two cells fromeach animal andone cell
per slice were analyzed. t tests were used to analyze differences
in the magnitude of the CCh response in the presence of the
active versus inactive peptide as well as to analyze the difference
in holding current in the presence of CCh relative to baseline
for each peptide. Similar analyses were used to assess the effect
of pirenzepine to block this effect.
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